InflaRx: Exciting Developments Ahead and Conference Details

InflaRx N.V. to Share Year-End Insights

InflaRx N.V. (NASDAQ: IFRX), a biopharmaceutical company known for its innovative approach to anti-inflammatory therapeutics, has made significant announcements regarding its upcoming financial results. The company plans to disclose its financial and operational results for the fourth quarter and full year 2024 on March 20, 2025. This marks a pivotal moment for the company as it aims to provide its stakeholders with crucial insights into its performance over the past year.

Engagement at Investor Conferences

In addition to the financial results announcement, InflaRx is gearing up to actively participate in two esteemed investor conferences. These events are expected to provide opportunities for the company to showcase its strategic vision and engage with investors directly.

Leerink Global Healthcare Conference Participation

The first conference is the Leerink Global Healthcare Conference, taking place from March 9 to March 12, 2025, in Miami Beach. A notable highlight of this event will be InflaRx's virtual fireside chat scheduled for March 10 at 10:40 AM ET. This session is anticipated to delve into the company's advances and clinical insights, enhancing investor understanding of its trajectory. Furthermore, the company will engage in one-on-one investor meetings, allowing for personalized discussions around its growth strategies.

H.C. Wainwright Conference Insights

Following the Leerink event, InflaRx will also feature at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025. Here, the company will present another virtual fireside chat at 8:30 AM ET. This setting will further facilitate discussions on the company's innovative solutions for complex autoimmune and inflammatory diseases.

About InflaRx and Its Innovations

InflaRx is at the forefront of biopharmaceutical innovation, specializing in therapies that precisely target the complement system to mitigate inflammation. The company is advancing its proprietary anti-C5a and anti-C5aR technologies, developing highly effective inhibitors that hold promise for a range of inflammatory conditions. InflaRx's flagship product, vilobelimab, represents a groundbreaking advance in treatment—an intravenously delivered monoclonal antibody that selectively targets free C5a, demonstrating clinical efficacy and safety across multiple studies. The company is also spearheading the development of INF904, an orally administered small molecule that targets the C5a receptor, further establishing its commitment to comprehensive solutions in the anti-inflammatory space.

Corporate Presence and Structure

Founded in 2007, InflaRx operates with a strong presence across Germany and the United States, with offices in Jena, Munich, and Ann Arbor, MI. This geographical diversity allows the company to tap into various talent pools and market opportunities, enhancing its innovation capabilities and reach in the biopharmaceutical landscape.

For Further Connections

If you seek more information or wish to connect with the company, InflaRx encourages direct inquiries. The contact details are as follows: Jan Medina, CFA, serves as the Vice President and Head of Investor Relations and can be reached via email at IR@inflarx.de. For broader inquiries in Europe, contact Katja Arnold or Laurie Doyle at inflarx@mc-services.eu, or reach out via phone at +49 89-210 2280. In the United States, you can connect at +1-339-832-0752.

Frequently Asked Questions

1. When will InflaRx report its 2024 financial results?

InflaRx plans to announce its financial results for the fourth quarter and full year 2024 on March 20, 2025.

2. What conferences will InflaRx participate in?

InflaRx will participate in the Leerink Global Healthcare Conference and the H.C. Wainwright Virtual Conference.

3. Who can I contact for investor relations at InflaRx?

For inquiries, you can contact Jan Medina, CFA, at IR@inflarx.de.

4. What is vilobelimab?

Vilobelimab is InflaRx's lead product candidate, a first-in-class anti-C5a monoclonal antibody that targets free C5a to reduce inflammation.

5. Where are InflaRx's offices located?

InflaRx has offices in Jena and Munich, Germany, and Ann Arbor, Michigan, USA.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.